Nilestriol
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Trade names | Wei Ni An |
| Other names | Nylestriol; LY-49825; Ethinylestriol cyclopentyl ether; EE3CPE; 17α-Ethynylestriol 3-cyclopentyl ether |
| Routes of administration |
By mouth |
| Drug class | Estrogen; Estrogen ether |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H32O3 |
| Molar mass | 380.528 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Nilestriol (INN) (brand name Wei Ni An; developmental code name LY-49825), also known as nylestriol (USAN, BAN), is a synthetic estrogen which was patented in 1971 and is marketed in China. It is the 3-cyclopentyl ether of ethinylestriol, and is also known as ethinylestriol cyclopentyl ether (EE3CPE). Nilestriol is a prodrug of ethinylestriol, and is a more potent estrogen in comparison. It is described as a slowly-metabolized, long-acting estrogen and derivative of estriol. Nilestriol was assessed in combination with levonorgestrel for the potential treatment of postmenopausal osteoporosis, but this formulation ultimately was not marketed.
See also
| ER |
|
||||||
|---|---|---|---|---|---|---|---|
| GPER |
|
||||||